Investing.com - Augmedix (NASDAQ: AUGX) reported first quarter EPS of $-0.120, $0.01 better than the analyst estimate of $-0.130. Revenue for the quarter came in at $13.47M versus the consensus estimate of $13.33M.
Guidance
Augmedix sees FY 2024 revenue of $52.000M-$55.000M versus the analyst consensus of $61.100M.
Augmedix's stock price closed at $2.34. It is down -50.110% in the last 3 months and down -27.100% in the last 12 months.
Augmedix saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Augmedix's stock price’s past reactions to earnings here.
According to InvestingPro, Augmedix's Financial Health score is "fair performance".
Check out Augmedix's recent earnings performance, and Augmedix's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar